Pages pUse SHIFT+ENTER to open the menu (new window).

This system library was created by the Publishing feature to store pages that are created in this site.

Immunoassay screen for the following drug classes or method groups: barbiturates, cannabinoids, cocaine, and ethanol. Test also includes specimen validity testing (creatinine) to detect adulteration, dilution, or substitution of the specimen.

Results of this test are presumptive. If confirmatory testing is desired, the confirmatory test(s) can be ordered as add-on (u-have) tests, utilizing the original urine collection, within 9 days of the original test.

This test is intended to compliment the test “Targeted Drug Panel, Urine” (TDPU).

​​​​Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Triploidy, 22q11.2 Deletion, Chromosome abnormalities, Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Klinefelter Syndrome, Triple X Syndrome, Jacob's Syndrome

​​​​​​CRMP-5; Anti-CV-2; Recoverin; Retinopathy; Ophthalmitis; Anti-CAR; CAR​

​Animal Allergen

Australian (Budgerigar)

Quaker

COL1A1-PDGFB

COL1A1/PDGFB

DFSP/GCF

t(17;22)​

This test does not include a pathology consultation. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge.

This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.

Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

​​blood pH, venous pH

​pH

Phenylalanine Includes Tyrosine
PKU (Phenylketonuria)
Tyrosine
Tyrosinemia
Hyperphenylalaninemia

Dilantin Free, Serum
Free Dilantin
Free Dilantin, Serum
Free Phenytoin
Dilantin, Total and Free (ORDER PNTFT) ​​

​Phenytoin, Free

​1-Palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanol (PLPEth)

1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol (POPEth)​

Anti-PLA2R; PLA2R​

17p- (17p deletion) or TP53, IGH (14q32) rearrangement, Monoclonal Gammopathy of Unknown Significance (MGUS), Multiple Myeloma, Plasma Cell Leukemia, t(4;14) - FGFR3/IGH, t(11;14) - CCND1/IGH, t(14;16) - IGH/MAF, t(14;20) - IGH/MAFB, +1q or 1q22

TI PLASFSO

​Fabrazzyme biomarker, Fabry disease biomarker

​PAI-1 Ag

JAK2 V617F

JAK2 exon 12

Polycythemia Vera

Myeloproliferative Neoplasm (MPN)

​Both DNA and RNA are extracted. The algorithm starts with a highly sensitive DNA-based JAK2 V617F test by allele specific polymerase chain reaction. If the JAK2 V617F result is negative or very low positive (0.06%-0.6%), JAK2 exon 12-15 Sanger sequencing test will be performed on the stored RNA sample. If a JAK2 V617F mutation (>0.6%) is detected, the algorithm stops and no further testing will be performed.

The Sanger sequencing covers JAK2 exons 12 through the first 90% of exon 15, which spans the region containing essentially all mutations reported in myeloproliferative neoplasms. The following algorithms are available in Special Instructions.

​​Acute Intermittent Porphyria (AIP)
Hereditary Coproporphyria (HCP)
PBG (Porphobilinogen)
Variegate Porphyria (VP)

Porphobilinogen Qnt, U (PBGU)

U PBGUSO

Acute Intermittent Porphyria (AIP)
Congenital Erythropoietic Porphyria (CEP)
Coproporphyrin
Hereditary Coproporphyria (HCP)
PBG (Porphobilinogen)
Porphyria Cutanea Tarda (PCT)
Porphyrins, Fractionation, Urine
Uroporphyrin
Variegate Porphyria (VP)

24 PORPHU

AB42/40 Ratio; Alzheimer's; Amyloid Beta; Amyloid Probability Score2; APOE; Dementia; Mild cognitive impairment; p-tau217; p-tau217 Ratio; Percent p-tau217; %p-tau217; C2N​

​The PrecivityAD2 blood test measures amyloid beta (Abeta) 42/40 ratio and percent tau phosphorylated at threonine-217 (%p-tau217). The results are then combined and used in a proprietary statistical algorithm to calculate the Amyloid Probability Score 2 (APS2). The APS2, Abeta 42/40 ratio and %p-tau217 are reported, however, individual Abeta42, Abeta40, phosphorylated tau217 and non-phosphorylated tau217 concentrations are not reported.

​Pregnenolone

​​Anti-PLA2R, PLA2R, Anti-THSD7A, Thrombospondin, THSD7​

​Procollagen I Intact N-Terminal

​​Prostate Specific Antigen, Total Hybritech

Adenine, Adenosine, Deoxyadenosine, Deoxyguanosine, Deoxyinosine, Guanosine, Hyperuricemias, Hypoxanthine, Inosine, Orotic Acid, Pyrimidine, Succinyladenosine, Thymidine, Uracil, Thymine, Uric Acid, Uridine, Xanthine, S-Sulfocysteine, Adenine phosphoribosyltransferase deficiency, Adenosine deaminase deficiency, Adenosine monophosphate deaminase deficiency, Adenylosuccinate lyase deficiency, AICAr transformylase/imp cyclohydrolase deficiency, Beta-ureidopropionase deficiency, Carbamoyl phosphate synthetase deficiency, Deoxyguanosine kinase deficiency, Dihydropyrimidinase deficiency, Dihydropyrimidine dehydrogenase deficiency, Hyperornithinemia-hyperammonemia-homocitrullinuria, Lesch-Nyhan syndrome, Molybdenum cofactor deficiency, Phosphoribosyl pyrophosphate synthetase deficiency, Primary hyperoxaluria, Purine metabolism disorders, Purine nucleoside phosphorylase deficiency, Pyrimidine metabolism disorders, Secondary hyperuricemia, Sulfite oxidase deficiency, Thymidine phosphorylase deficiency, Uridine monophosphate synthetase deficiency, Xanthine dehydrogenase and xanthine aldehyde oxidase dual deficiency, Xanthine dehydrogenase deficiency, Xanthine dehydrogenase/xanthine aldehyde oxidase/sulfite oxidase combined deficiency

​Uracil, Thymine, Adenine, Hypoxanthine, Xanthine, Orotic, Dihydroorotic Acid, Uric Acid, Deoxythymidine, Deoxyuridine, Thymidine, Uridine, Deoxyadenosine, Deoxyinosine, Deoxyguanosine, Adenosine, Inosine, Guanoasine, 5-Aminoimidazole-4-carboxyamide 1-beta-D-ribofuranoside (AICAR), Succinyladenosine, S-Sulfocysteine, Dihydrouracil, Dihydrothymine, N-carbomoyl-B-alanine, N-carbomoyl-B-aminoisobutyric Acid